Market Insights Health Medical Technology Medical Devices

Diabetes Care Devices - EMEA

EMEA

Revenue in the Diabetes Care Devices market market in EMEA is projected to reach US$7.93bn in 2024.
Revenue in this region is expected to exhibit an annual growth rate (CAGR 2024-2029) of 12.18%, which will lead to a market volume of US$14.09bn by 2029.
In a global context, the majority of revenue is anticipated to be generated the United States, amounting to US$11,710.00m in 2024.
The diabetes care devices market in Germany is increasingly focused on integrating digital health technologies to enhance patient management and outcomes.

Key regions: Netherlands, Japan, France, Italy, China

Market

Region

Region comparison

Currency

Analyst Opinion

The Diabetes Care Devices Market in EMEA is witnessing considerable growth, fueled by advances in technology, increasing prevalence of diabetes, and heightened consumer awareness. These factors are driving demand for innovative monitoring and management solutions across the region.

Customer preferences: Consumers in the EMEA Diabetes Care Devices Market are increasingly favoring personalized and connected solutions to manage their health more effectively. This trend is influenced by a growing awareness of diabetes as a chronic condition and the importance of lifestyle choices. Additionally, younger demographics are embracing mobile health applications and smart devices that integrate seamlessly into their daily routines. Cultural shifts towards preventive care and self-management are promoting the adoption of innovative technologies, enhancing patient engagement and adherence to treatment regimens.

Trends in the market: In the EMEA Diabetes Care Devices Market, there is a notable shift towards the adoption of smart insulin delivery systems and continuous glucose monitoring (CGM) technologies. Patients are increasingly opting for devices that offer real-time data and automated insulin adjustments, enhancing their ability to manage diabetes effectively. In addition, the integration of artificial intelligence in diabetes management tools is gaining momentum, providing personalized insights and predictive analytics. This trend highlights the importance of data-driven solutions, prompting manufacturers to innovate and collaborate with tech companies, thereby reshaping the competitive landscape and improving patient outcomes.

Local special circumstances: In EMEA, the Diabetes Care Devices Market is influenced by diverse healthcare systems and varying levels of reimbursement for diabetes technologies. Countries with well-established healthcare frameworks, like Germany and France, promote the adoption of advanced devices through strong insurance coverage. In contrast, regions with less robust systems face barriers to access due to high out-of-pocket costs. Additionally, cultural attitudes towards technology and health management vary widely, impacting patient willingness to adopt smart devices and digital tools for diabetes care.

Underlying macroeconomic factors: The Diabetes Care Devices Market in EMEA is significantly shaped by macroeconomic factors such as national healthcare expenditure, reimbursement policies, and economic stability. Countries with robust economies and comprehensive health policies, like Sweden and the Netherlands, facilitate higher adoption rates of innovative diabetes technologies through extensive insurance coverage and funding for medical devices. Conversely, nations facing economic challenges or austerity measures may experience delayed access to these devices due to budget constraints and prioritization of essential healthcare services. Additionally, the rising prevalence of diabetes across the region necessitates increased investment in diabetes care solutions, further propelling market growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.